Retinal pathologies are frequently accompanied by retinal vascular responses, including the formation of new vessels by angiogenesis (neovascularization). Pathological vascular changes may also include less well characterized traits of vascular remodeling that are non-neovascular, such as vessel pruning and the emergence of dilated and tortuous vessel phenotypes (telangiectasis). The molecular mechanisms underlying neovascular growth versus nonneovascular remodeling are poorly understood. We therefore undertook to identify novel regulators of non-neovascular remodeling in the retina by using the dystrophic Royal College of Surgeons (RCS) rat and the retinal dystrophy 1 (RD1) mouse, both of which display pronounced non-neovascular remodeling. Gene expression profiling of isolated retinal vessels from these mutant rodent models and wild-type controls revealed 60 differentially expressed genes. These included the genes for apelin (Apln) and for its receptor (Aplnr), both of which were strongly up-regulated in the mutants. Crossing RD1 mice into an Apln-null background substantially reduced vascular telangiectasia. In contrast, Apln gene deletion had no effect in two models of neovascular pathology [laser-induced choroidal neovascularization and the very low density lipoprotein receptor (Vldlr)-knockout mouse]. These findings suggest that in these models apelin has minimal effect on sprouting retinal angiogenesis, but contributes significantly to pathogenic non-neovascular remodeling. (Am J
Development of the retinal vasculature is initiated by blood vessels in the optic nerve head. These vessels form sprouts that develop into a primitive vascular plexus by the process of angiogenesis. 1 Initially, a simple network is established at the inner surface of the retina; from there, vascular sprouts subsequently penetrate the retina to form a second, deeper plexus. To generate the patterned and hierarchically branched network characteristic of the mature retinal vasculature, these primary vascular plexuses undergo extensive remodeling to achieve the final vascular configuration. Much research has focused on sprouting angiogenesis in the retina because of its link to pathology in the adult (referred to as neovascularization), including blinding complications in diseases such as diabetic retinopathy or agerelated macular degeneration. Various trophic factors have been identified as important regulators of the process. with the vascular endothelial growth factors (VEGFs) and their receptors being viewed as critical components. 2 Indeed, therapeutic targeting of VEGF in ocular angiogenesis has resulted in improved clinical outcome in a number of sightthreatening conditions. Nevertheless, other factors, including transforming growth factor ␤1 (TGF-␤1), basic fibroblast growth factor (bFGF), insulin-like growth factor 1 (IGF-1), platelet-derived growth factor (PDGF), and angiopoietin are also thought to contribute, either by modifying the VEGF response or by independently regulating the remodeling of existing vessels.
Non-neovascular remodeling is a characteristic of many sight-threatening retinal diseases. For instance, adult vessels can become telangiectatic (tortuous and dilated) in diseases such as macular telangiectasia, 3 diabetic retinopathy, 4 Coats' disease, 5 radiation-induced retinal telangiectasia, 6 and ataxia-telangiectasia. 7 Similarly, in the retinitis pigmentosa (RP) family of diseases the degeneration of photoreceptors leads to remodeling and attenuation of the retinal vasculature. 8 Morphologically similar patterns of non-neovascular remodeling are also observed in rodent models with photoreceptor degeneration, such as the Royal College of Surgeons (RCS) rat and the retinal degeneration 1 (RD1) mouse. In the RCS rat, retinal degeneration occurs because of a mutation in the Mertk gene, resulting in defective phagocytosis of the outer segments and photoreceptor cell death. 9, 10 The deeper plexus of the retinal vasculature subsequently becomes leaky and develops telangiectatic vessels. 11 In the RD1 mouse, rapid photoreceptor loss due to the presence of a mutation within the photoreceptor cGMP phosphodiesterase gene begins at postnatal day 8 (P8), with complete rod photoreceptor atrophy occurring by 4 weeks of age. 12, 13 This mutation also results in accompanying vascular atrophy. Vessels develop normally up to P12, but loss of capillaries within the deep vascular plexus follows, with subsequent appearance of telangiectatic vessels.
14, 15 The remodeling of existing vessels, such as the formation of telangiectasia, is clearly an important phenomenon that contributes to pathogenesis in a number of ocular and nonocular diseases. Although factors that contribute to developmental remodeling have been identified, 16 those responsible for driving non-neovascular pathogenic modifications remain poorly defined.
In the present study, we investigated non-neovascular remodeling in two rodent models with retinal degenerative disease, the RCS rat and the RD1 mouse. Having established that the vascular changes, including the development of telangiectatic vessels, are non-neovascular and anatomically similar in both models, we embarked on gene expression analysis of isolated retinal microvascular fragments to identify candidate genes contributing to the process. A group of differentially expressed genes were identified, of which two [apelin (Apln) and its receptor (Aplnr)] were investigated further to establish their potential role in non-neovascular remodeling.
In the retina, Aplnr transcripts were uniquely expressed by endothelial and/or associated mural cells, whereas Apln was expressed predominantly by vessels but also other cells of the retina. Analysis of Apln-knockout mice revealed fewer radial veins and arteries and an increase in arteriovenous crossover. Furthermore, during retinal vascular development, radial veins failed to remodel into deep drainage venules in the Apln-knockout mice. In RD1 mice lacking the apelin gene, there was a similar failure to develop these deep drainage venules. Crucially, however, there was also a significant reduction in pathogenic telangiectatic vessels arising in the intermediate vascular plexus. These data indicate a key role for apelin in both developmental and pathogenic non-neovascular remodeling.
Materials and Methods

Animals
RD1 mice 12 and Vldlr Ϫ/Ϫ mice 17 were purchased from the Jackson Laboratory (Bar Harbor, ME). Control C57BL/6J mice were purchased from Harlan Laboratories (Blackthorn, UK). RCS dystrophic and congenic rats were bred from an established in-house colony; the Apln-knockout mice were was a generous gift from Dr. J.M. Penninger, Vienna, Austria.
18 Double-mutant mice were generated by crossing an Apln-knockout mouse with an RD1 mouse to generate heterozygote offspring (R Ϫ/ϩ /A Ϫ/ϩ ). These were crossed, and the resultant offspring were genotyped to identify animals that were both homozygous RD1 mutants and heterozygous Apln mutants (R Ϫ/Ϫ /A Ϫ/ϩ ). These mice were then crossed to generate RD1 homozygous mutants that were also either homozygous wild type for Apln (R Ϫ/Ϫ /A ϩ/ϩ ) or homozygous mutant for Apln (R Ϫ/Ϫ /A Ϫ/Ϫ ). The same procedure was applied to generate double-Vldlr and Apln-knockout mice. All experiments were performed in accordance with the Animals (Scientific Procedures) Act and ethically approved by the UK Home Office.
Vessel Isolation
Rat or mouse retinas were enzymatically digested in collagenase/dispase (1 mg/mL; Roche, Welwyn, UK) and DNase (20 U/mL; Ambion, Warrington, UK) at 37°C for 45 to 60 minutes. The microvessels were extracted using either anti-mouse or anti-rat PECAM-1 antibodies (BD Bioscience, Oxford, UK, and AbD Serotec, Kidlington, UK, respectively), followed by either sheep anti-mouse or sheep anti-rat IgG-conjugated magnetic beads (Dynabead; Invitrogen, Paisley, UK) and magnetic separation. The bead-bound vessels (vessel-enriched) and vesseldepleted fractions were separately lysed for Western blotting or for RNA extraction and analysis.
Immunohistochemistry
Bead-bound vessels were paraformaldehyde-fixed and then dried onto SuperFrost microscope slides (VWR International, Leicestershire, UK). They were then stained with anti-collagen IV (AbD Serotec), caveolin 1 (BD Biosciences), fibronectin (Millipore-Chemicon International, Temecula, CA), or ␣-smooth muscle actin (ASMA) (Sigma-Aldrich, Dorset, UK) antibodies, followed by incubation with their respective Alexa Fluor 555-and 488-labeled secondary antibodies (Invitrogen).
Retinal whole mounts were fixed and stained as described previously. 1 Briefly, eyes were rapidly fixed in 2% paraformaldehyde before retinal dissection in PBS and refixation in 100% ice-cold methanol overnight at Ϫ20°C. Retinas were rehydrated, blocked in blocking buffer (3% Triton-X-100, 1% Tween-20, 0.5% bovine serum albumin in PBS) and incubated overnight with either rabbit-antimouse collagen IV (AbD Serotec) or fluorescein isothiocyanate-isolectin B4 (Vector Laboratories, Peterborough, UK). Retinas were then washed before incubation with Alexa Fluor 488-labeled secondary antibodies (Invitrogen) and mounted in Mowiol 4-88 reagent (Merck Chemicals, Nottingham, UK) and examined by fluorescence (Leica) or confocal (Zeiss LSM 510) light microscopy. For quantification of telangiectatic vessels, the number of 360-degree turns in the vessels were counted per retina. For evaluating the vascular growths in the Vldlr Ϫ/Ϫ animals, the numbers of collagen IV-positive vascular tufts on the outer retina were counted per retina and averaged.
Laser-Induced Choroidal Neovascularization
Laser-induced choroidal neovascularization (CNV) and quantification using fundus fluorescein angiography was performed as described previously. 19 Three laser lesions per eye were delivered at two to three disk diameters away from the optic nerve head with a slit-lamp-mounted diode laser system (Keeler SL-16, Windsor, UK; wavelength: 680 nm; laser settings: 210 mW power, 100 ms duration, 100 m spot diameter). At 2 weeks after laser induction, in vivo fundus fluorescein angiography was performed, and images from the early phase (90 seconds after fluorescein injection) and late phase (7 minutes) were obtained using a Kowa Genesis small animal fundus camera with appropriate filters (Kowa Optimed, Torrance, CA). The pixel area of CNV-associated hyperfluorescence was quantified for each lesion using ImageJ version 1.44i image analysis software (NIH, Bethesda, MD). To quantify the volume of the CNV lesions, whole mounts of the eye cup were prepared by carefully peeling off the neural retina and exposing the CNV attached to the retinal pigment epithelium (RPE). CNV lesions were immunostained for PECAM-1 using the protocol described above for immunohistochemistry. Confocal sections were obtained using a Zeiss LSM 710 upright confocal microscope using a 40ϫ water immersion plan Apochromat lens. Z-stacks were captured and three-dimensional images were reconstructed, followed by surface rendering, using Imaris software version 7.3 (Bitplane, Zurich, Switzerland). CNV volume was calculated using the Imaris measurement module.
SDS-PAGE and Western Blotting
Proteins were separated by SDS-PAGE, transferred onto a nitrocellulose membrane by wet transfer, bovine serum albumin blocked, and incubated with goat anti-VE-cadherin (Santa Cruz Biotechnology, Heidelberg, Germany), followed by HRP-conjugated secondary antibodies (Santa Cruz Biotechnology). Blots were developed using luminescent substrates (Roche, Welwyn, UK). The gel was subsequently stained using Coomassie Blue and destained to visualize the bands. Densitometry was performed using ImageJ software version 1.44i.
Quantitative Real-Time PCR
RNA was extracted using TRIzol reagent (Invitrogen), followed by an RNeasy clean-up (Qiagen, West Sussex, UK). RNA was DNase-treated and reverse-transcribed using Qiagen QuantiTect kits, and real-time PCR was performed using Power SYBR PCR master mix (Applied Biosystems, Paisley, UK). The following primers were used: mouse VE-cadherin (Fwd: 5=-CATAAACAACAAT-GACAACACC-3=, Rev: 5=-GATGATCAGCAAGGTAAT-CAC-3=); PDGFR-␣ (Fwd 5=-TGTAGACTTGGAGAA-TACTGC-3=, Rev: 5=-CGCTCTCACACACTTACC-3=) rhodopsin (Fwd: 5=-TGGTGGTCTGTTGCTCTC-3=, Rev: 5=-GCTGCTCTATCACATTCCC-3=); desmin (Fwd: 5=-TC-ATCGCCCTTCCCCTTC-3=, Rev: 5=-GTCCACAAACTCG-GTCCTG-3=) APLNR (Fwd: 5=-GGGAGTAAGTTTGGG-AAAGAG-3=, Rev: 5=-TGGAATATGTCTTGTCCTTGG-3=); APLN (Fwd: 5=-GGCCTTCTCCGTCTTTGTCG-3=, Rev: 5=-CCCTCTTGTGCTTCTATCTCTCC-3=); PECAM1 (Fwd: 5=-GCCAGTCACTTGAAGACAGACC-3=, Rev: 5=-TGGA-ACGGAAAGGAAGATCAAGG-3=); ␤-actin (Fwd: 5=-TCCA-AGTATCCATGAAATAAGTGG-3=, Rev: 5=-GCAGTACATA-ATTTACACAGAAGC-3=); VEGF (Fwd: 5=-GACTTGTG-TTGGGAGGAGGA-3=,_Rev: 5=-TCTGGAAGTGAGCCAA-TGTG-3=). Rat APLNR (Fwd: 5=-TTGGTCTCTTCTCTGTC-AGGAC-3=, Rev: 5=-GTCACTCTTTCACAACCTTACCC-3=); APLN (Fwd: 5=-CGTGTAGGGAGGTGAGTGCTTGTA-TC-3=, Rev: 5=-CGAACAGATGCCAAAGGACTTAAAAG-GG-3=); ␤-actin (Fwd: 5=-ATCGTGCGTGACATTAAA-3=, Rev: 5=-GCCACAGGATTCCATACC-3=); VEGF (Fwd: 5=-GGTGACCAAGCACGGTGGTCC-3=, Rev: 5=-TAAGAA-GGACGAAAGACCACACCGG-3=). Genotyping primers were as follows: RD1 mutant 20 : 5=-GTAAACAGCAA-GAGGCTTTATTGGGAAC-3=, RD1 wild-type: 5=-TACCCA-CCCTTCCTAATTTTTCTCAGC-3=, RD1 common: 5=-TGA-CAATTACTCCTTTTCCCTCAGTCTG-3=; APLN mutant: 5=-GACAGTTTCTCTAACTCAAAGGGCC-3=, APLN wild type: 5=-GCTTCCTTCTTCTAGTCCTGTTCCA-3=, APLN common: 5=-ATGTCTGGGTGTAGGTCCATAAAGG-3= (MWG Biotech, London, UK).
Microarrays
Microvessels were isolated from six nondystrophic and six dystrophic RCS rat retinas, all rats at 5 months of age. The RNA was extracted, amplified, and labeled for microarray analysis using an Affymetrix two-cycle labeling kit according to the manufacturer's instructions (Affymetrix, High Wycombe, UK). Similarly, RNA was extracted from isolated vessels from 12 C57BL/6J mice (15 weeks of age) and 12 RD1 mice (18 weeks of age) and processed for microarray analysis. This was repeated four times for each animal model, providing RNA for four chips per animal model. RNA quality was checked using an Agilent Technologies (Santa Clara, CA; Waldbronn, Germany) bioanalyzer before hybridization to Affymetrix mouse 430.2 or rat 230.2 gene arrays at the UCL Wolfson Institute and UCL Institute for Child Health Microarray Facility. The data were analyzed using Bioconductor 2.0 and RGui software version 2.5.1 as described previously. 21 
Statistical Analysis
Paired and unpaired data were analyzed using a Student's t-test. A maximum P value of 0.05 was considered significant. For the microarrays, statistical analysis was done using the RGui LIMMA software package version 2.5.1 as described previously. 21 A false discovery rate statistical post hoc test (q Յ 0.05) was used for the RD1 mouse, and a log 2 fold change of Ն2 with a P value of Յ0.01 was used for the RCS rat.
Results
RCS Dystrophic Rats and RD1 Mice Display Similar Vascular Remodeling
Detailed examination of the retinal vasculature of RCS dystrophic rats and RD1 mice was performed to establish the pattern of vascular remodeling in these animals. The retinas were flat-mounted and examined by immunostaining for collagen IV or isolectin B4. Compared with nondystrophic RCS rats ( Figure 1 , A and B), the dystrophic RCS rat at 5 months of age had substantial retinal thinning due to photoreceptor degeneration, as well as extensive vascular abnormalities across the outer retina ( Figure 1 , C and D). Vessels from the deeper plexus had remodeled into telangiectatic vascular complexes that frequently consisted of length-expanded capillaries, folded in a corkscrew-like fashion. In some instances, these complexes were directly associated with the RPE. These observations are consistent with previous reports. 11, 22 In 4.5-month-old RD1 mice, we observed morphologically similar telangiectatic vessels extending from the remaining neuroretina toward the subretinal space (Figure 1 . Similar abnormalities have been reported previously and are most probably the precursors to RPE-associated vascular complexes observed from 6 months of age. 15 At the earlier time points investigated, no association of vessels with the RPE was observed. The telangiectatic vessels stained positively for isolectin B4 ( Figure 1I ), demonstrating that they contained viable endothelial cells and were not acellular vessel ghosts. Furthermore, isolectin staining did not reveal any evidence of filopodia or vascular sprouting during this phase of vascular alteration, confirming that these vascular abnormalities do not form by sprouting angiogenesis but by non-neovascular remodeling.
Consistent with this observation, whole-retina quantitative PCR (qPCR) for VEGF on the RCS rat and RD1 mouse (at 5 months and 4.5 months of age, respectively) revealed only small changes in transcript expression, relative to the wild type ( Figure 1N ). To compare VEGF levels in the RCS rat and RD1 mouse with a rodent model of retinal neovascularization, we measured VEGF mRNA expression in the Vldlr Ϫ/Ϫ mouse. 17, 23 In this mouse, which models retinal angiomatous proliferation, there is marked intraretinal neovascularization commencing from approximately P14 and continuing through to approximately P30. By 4 months of age, a portion of these abnormalities appear as plaques containing associated RPE on the outer retina ( Figure 1 , L and M). 24 We therefore evaluated whole-retina VEGF transcript expression by qPCR at P21 and observed a substantially greater fold change in VEGF expression, relative to the RCS rat or RD1 mouse ( Figure 1N ). In conjunction with the absence of tip cells, as judged by a lack of endothelial cell filopodia, these results suggest that VEGF-induced neovascularization is unlikely to be a major contributor to the observed remodeling of vessels in the RD1 mouse and RCS rat.
Differentially Expressed Genes in Retinal Microvessels of the RCS Rat and RD1 Mouse
Irrespective of disease causation, we hypothesize that downstream non-neovascular pathogenic changes are likely to be mediated by common mechanisms. To gain insight into the transcriptional programming that drives such vascular abnormalities, retinal microvessel fragments were purified from the retina of the RCS and RD1 mouse using anti-PECAM-1 magnetic beads (see Supplemental Figure S1A at http://ajp.amjpathol.org). Vesselenriched and vessel-depleted fractions were obtained and examined by phase contrast and epifluorescent microscopy (see Supplemental Figure S1B http://ajp. amjpathol.org), and qPCR and Western blotting confirmed good vessel recovery and substantial enrichment of endothelial cell markers (see Supplemental Figure S1 , C and D, at http://ajp.amjpathol.org). To test whether the vessel-enriched fraction contained other cell types besides endothelial cells, we performed qPCR with primers for the pericyte marker desmin, the glial marker PDGFR␣, and the photoreceptor marker rhodopsin. The resulting data revealed contamination of glial cells, minor contamination by pericytes, but virtually no contamination from photoreceptors (see Supplemental Figure S2 , A-C, at http://ajp.amjpathol.org). Global gene expression analysis was then undertaken to identify genes in the endothelial-enriched fractions that may contribute to retinal non-neovascular remodeling in the RD1 mouse and RCS rat. Microarray analysis followed by false discovery rate statistical post hoc test with an adjusted P value of Յ0.05 revealed 3270 genes that were differentially regulated in the RD1 mouse. Reducing the stringency for the RCS rat by removing the post hoc test and using a fold change cutoff of Ն2 and a P value of Յ0.01 revealed 341 differentially regulated genes. Of these, 60 transcripts were common to the RD1 mouse and the RCS rat (see Supplemental Table S1 at http:// ajp.amjpathol.org). Of the differentially regulated genes, the small secreted signaling peptide apelin (Apln) and its receptor (Aplnr), both of which have previously been implicated in vascular development and pathology, [25] [26] [27] [28] [29] were significantly up-regulated. Also up-regulated were adrenomedullin (Adm) and plasmalemma vesicle associated protein (Plvap); these are vascular-associated genes that have the potential to affect vascular function.
Other genes found to be up-regulated included glial fibrillary acidic protein (Gfap) and the GABA A receptor (Gabra1) derived from contaminating astroglia and neurons, respectively. Notably, the GABA A receptor has been implicated in vascular remodeling in the brain. 30 However, many of the genes lacked any obvious functional connection to the vasculature. Furthermore, many of the down-regulated genes most likely resulted from the loss of contaminating photoreceptors in the degenerate retinas (ie, phosducin, recoverin, and retbindin, among others). Because of the increasingly prevalent notion that apelin and its receptor affect vascular development and pathology, Apln and Aplnr were chosen for further analysis.
Apelin and Its Receptor Are Up-Regulated in the Retinal Vasculature of the RCS Rat and RD1 Mouse
The microarray gene expression profiling of the dystrophic RCS rat and RD1 mouse retinal vasculature revealed an increase in the expression of Aplnr by 2.7-fold and 5.7-fold and of Apln by 8.9-fold and 2.9-fold, respectively (see Supplemental Table S1 at http://ajp.amjpathol.org). To validate the microarray gene expression data, we undertook qPCR analysis on RNA isolated from total mouse and rat retinas. In agreement with the microarray results, a statistically significant increase in Apln and Aplnr expression was observed in both animal models (Figure 2A ). To establish whether the observed increase in retinal Aplnr mRNA in the animal models resulted in an increase in protein expression, Aplnr levels from wholeretina lysates of the RCS rat and RD1 mouse were evaluated by Western blot analysis. In both animal models, we detected a significant increase in Aplnr, relative to control levels ( Figure 2 , B and C). To determine whether expression in the retina was restricted to the vasculature we analyzed by qPCR the vessel-enriched and the vessel-depleted fractions of mouse retinal preparations. Aplnr expression was restricted to the vessel-enriched sample, indicating that the receptor is not expressed by cells of the neural retina. However, although Apln expression was predominantly vascular, it was also observed in the vessel-depleted fraction ( Figure 2D) suggesting that other cells, such as Müller glia, are also a potential source of the ligand. The expression of Aplnr was then confirmed by immunohistochemistry in the RCS rat, with a vascular pattern of staining observed in both congenic and dystrophic animals (Figure 2, E-H) . Apln and Aplnr are increased in the RCS and RD1 rodent retina. A: Aplnr and Apln expression as measured by qPCR in retinal extracts of RCS dystrophic rats (n ϭ 3), relative to congenic RCS rats (n ϭ 3), both 20 weeks of age, and of RD1 mice (n ϭ 3), relative to wild-type C57BL/6J mice (n ϭ 3), both 4.5 months of age. B: Protein expression of Aplnr in RCS dystrophic versus nondystrophic rat retina (n ϭ 4) and in RD1 versus C57BL/6J mouse retina (n ϭ 4). C: Representative findings of densitometry performed on three independent Western blots. D: Vessels were purified from mouse retinas and the vessel-enriched and vessel-depleted fractions were analyzed for Aplnr and Apln expression by qPCR. Data are expressed as means Ϯ SEM (n ϭ 3). *P Յ 0.05; **P Յ 0.01, Student's t-test. E-H: Congenic (E) and dystrophic (F-H) RCS rat retinas were flat-mounted and immunostained for Aplnr. At higher magnification (H), Aplnr staining is visible in telangiectatic vessels (arrowheads). Scale bars: 100 m (E-G); 20 m (H).
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Loss of Apelin Has Little Effect on Retinal Developmental Vascular Sprouting but Does Affect Developmental Vascular Remodeling
Having established that the remodeled pathogenic vessels of the RCS rat and RD1 mouse retina express increased levels of apelin and its receptor, we next investigated whether loss of apelin affected normal retinal vascular development and remodeling. As has been previously reported, 31 developmental retinal angiogenesis in the Apln Ϫ/Ϫ mouse 18 is largely unaffected, with only a small decrease in branching of the deeper plexus being observed (P Ͻ 0.01; Figure 3 , A-C). We therefore undertook a more detailed study of the vascular organization in these animals. Although whole-mounted retinas at P8 and P21 from the Apln Ϫ/Ϫ mouse revealed no gross vascular abnormalities, in the superficial layer the total number of radial veins and arteries was decreased, relative to C57BL/6J mice (P Ͻ 0.05; Figure 3D ). Moreover, arteriovenous crossings were observed with much greater frequency (P Ͻ 0.01; Figure 3 , E and F). On closer examination, we also found clear evidence of abnormal remodeling of radial veins in Apln Ϫ/Ϫ mice. In control C57BL/6J mice, veins develop in a strictly alternating pattern between arteries during superficial plexus development. Subsequently, as the deeper plexus develops, some (but not all) of the superficial veins are reorganized, through remodeling of existing vessels, into deeper plexus drainage veins (Figure 3 , G-I; see also Supplemental Movies S1 and S2 at http://ajp.amjpathol.org). This leads to a relocation of veins from the superficial to the deeper plexus, although not by physical vessel translocation but rather by network remodeling. This remodeling process was disturbed in Apln Ϫ/Ϫ mice, with most superficial veins remaining at the surface, and with dramatically reduced development of drainage veins in the deeper plexus (Figure 3, J-L) . Quantification of the number of these remodeled veins per retina revealed a significant reduction in the Apln Ϫ/Ϫ mice, relative to control animals ( Figure 3M ), demonstrating a prominent role for apelin in remodeling the retinal vascular plexus. To corroborate our findings we conducted in situ hybridization to detect Aplnr mRNA expression in retinal flat mounts. A positive signal was observed in the superficial radial and deep drainage retinal veins of the wild-type mouse at P11 and in the remodeled interconnecting vessels linking these two vessels (Figure 3, N and O) .
Apelin Does Not Contribute to the Development of Choroidal Neovascularization or Pathogenic Intraretinal Neoangiogenesis
To ascertain whether apelin contributes to pathogenic neovascularization in the retina, we investigated whether laser-induced CNV, a feature of wet age-related macular degeneration, was attenuated in Apln Ϫ/Ϫ mice. CNV was induced in Apln Ϫ/Ϫ and in control C57BL/6J mice, and fluorescein angiography was used to determine the size and permeability of the neovascular lesion. Neither at the early phase of fluorescein angiography, which reflects the size of the neovasculature, nor at the late phase, which indicates degree of fluorescein leakage, did findings differ between the Apln Ϫ/Ϫ and control mice ( Figure  4, A-E) . Furthermore, analysis of lesion area (see Supplemental Figure S3 at http://ajp.amjpathol.org) and volume showed no difference between Apln Ϫ/Ϫ and control mice (Figure 4, F-H ). These data demonstrate that apelin does not contribute significantly to the size or permeability of the CNV lesion.
Because subretinal neoangiogenesis in CNV is derived from the choroid, and not the retina, we next used the Vldlr Ϫ/Ϫ mouse, which exhibits features of human retinal angiomatous proliferation, a condition found in a subset of neovascular age-related macular degeneration patients in which intraretinal neovascularization originates from the deep vascular plexus and extends toward the RPE. Apln Ϫ/ϩ and Vldlr Ϫ/ϩ mice were crossed to generate homozygous Vldlr/wild-type Apln (V Ϫ/Ϫ /A ϩ/ϩ ) and homozygous knockout Vldlr/homozygous knockout Apln (V Ϫ/Ϫ /A Ϫ/Ϫ ) littermates. These offspring were then examined for the occurrence of neovascular growths emerging from the deep vascular plexus at P28 (Figure 4, I and J) . The absence of apelin had no significant effect on the number of neovascular sprouts, compared with Vldlr Ϫ/Ϫ alone ( Figure 4K ). As with the CNV lesions, these observations provide strong evidence that apelin does not have any significant effect in these models of pathogenic neovascularization in the retina. 
Loss of Apelin Attenuates Pathogenic NonNeovascular Remodeling in the Retina of the RD1 Mouse
Having established that apelin is not required for pathogenic neoangiogenesis in the CNV and Vldlr Ϫ/Ϫ animal models, we next tested whether apelin is involved in nonneovascular remodeling induced by photoreceptor degeneration as described above. Apln Ϫ/Ϫ and RD1 mice were crossed to generate homozygous RD1 mutant/wild-type Apln (R Ϫ/Ϫ /A ϩ/ϩ ), homozygous RD1 mutant/heterozygous Apln (R Ϫ/Ϫ /A Ϫ/ϩ ), or homozygous RD1 mutant/homozygous knockout Apln (R Ϫ/Ϫ /A Ϫ/Ϫ ) littermates. These progeny were examined for the occurrence of retinal vascular remodeling at 4.5 months of age. Similar to RD1 mutant animals, all crossed mice underwent thinning of the neuroretina due to photoreceptor loss (data not shown). In R Ϫ/Ϫ /A ϩ/ϩ ( Figure 5 , A and B) and R Ϫ/Ϫ /A Ϫ/ϩ animals ( Figure 5 , E and F), tortuous telangiectatic vessels were apparent throughout the deep vascular network, either as part of the capillary network or as vessels linked to the deep drainage veins, as described above for the RD1 mouse. In contrast, RD1 animals that lacked apelin (R Ϫ/Ϫ /A Ϫ/Ϫ ) exhibited a marked reduction in telangiectatic vessels ( Figure 5, I and J). Most notably, the tortuous remodeled deep drainage vessels, as described above, were completely absent ( Figure 5M) .
Examination of the spatial organization of the superficial radial veins in the R Ϫ/Ϫ /A ϩ/ϩ mice revealed that they penetrated the deeper plexus in a fashion identical to that seen in the RD1 mouse ( plexus, which was not affected. We therefore investigated whether depleting apelin reduced the number of telangiectatic capillaries in this cohort of vessels, because these telangiectatic capillaries would be independent of the loss of deep draining veins. In the R Ϫ/Ϫ /A ϩ/ϩ and R Ϫ/Ϫ /A ϩ/Ϫ mice, numerous telangiectatic capillaries were observed ( Figure 5, N and O) . In the R Ϫ/Ϫ /A Ϫ/Ϫ mice, abnormal capillaries were also observed, but these exhibited reduced and negligible tortuosity, compared with those seen in the R Ϫ/Ϫ /A ϩ/ϩ mice, respectively (Figure 5, O and P) . When the level of tortuosity was quantified by enumerating the number of vessels with 360-degree turns per retina, the degree of telangiectasia in the R Ϫ/Ϫ /A Ϫ/Ϫ mice was substantially reduced ( Figure  5Q ). These data provide strong evidence that apelin regulates the pathogenic non-neovascular remodeling of microvessels, particularly with respect to telangiectasia.
Discussion
Gene expression analysis of the vasculature of two animal models of retinal degeneration with associated vascular remodeling revealed a number of differentially expressed genes common to both pathologies. Two of these genes, encoding the small secreted peptide Apln and its cognate receptor Aplnr, were significantly upregulated, relative to control vessels, and were selected for further investigation. Apelin exists as an inactive 77-amino-acid preproprotein and as various active cleavage products, of which apelin-13 is the most biologically active. The apelin receptor, for which apelin is the only known ligand, is a G protein-coupled receptor (GPCR) that associates with both G␣i and Gq heterotrimeric G proteins to induce activation of Akt/ERK and PLC, respectively. 32, 33 Current data suggest that the vascular endothelium is a major target of apelin signaling, with various downstream effects such as increased cell division and migration 27, 34 and eNOS activation and NO production. 35, 36 In addition, apelin has been reported to modulate developmental angiogenesis, 25, 26, 28, 31, 34, 37 pathogenic angiogenesis, 26, 29, 37, 38, 39, 40, 41 and angiogenesis in in vitro assays. 27, 34 Although the overall interpretation of many of these studies is that apelin is involved in angiogenesis, close inspection reveals that that the evidence is far from conclusive. For example, many studies do not distinguish between sprouting angiogenesis and vascular remodeling. Thus, the common readouts used to assess angiogenesis, such as vessel density, branch points and vascular structural abnormalities, may be altered as result of vascular remodeling alone (eg, increased or decreased vessel pruning). Moreover, many studies simply demonstrate a correlation between Apln/Aplnr expression and angiogenesis but do not demonstrate a causal link and others are based on imperfect in vitro cell culture models. Similarly, in the clinical setting, apelin expression is significantly increased in the vitreous of patients with proliferative diabetic retinopathy, 42, 43 but again both neovascularization and vascular remodeling occur. More consistent with our findings is the observation that apelin is necessary for normal vessel caliber development in various tissues. 44, 45 Nevertheless, as discussed below, the apelinergic pathway may contribute to angiogenesis, especially in the context of modifying the VEGF response.
We observed that Apln and Aplnr are coexpressed in the retinal microvasculature, implying the presence of autocrine signaling. Although Aplnr expression in the retina is restricted to the retinal vessels, demonstrating the vasculature as the primary target of apelin activity, some apelin expression was also observed in the nonvascular compartment. This latter finding may be due to expression in Müller cells, 46 which is pertinent, given that Müller cell end-feet associate closely with the inner retinal vasculature and are likely to play an important part in determining vascular function. In the vasculature of the RCS and RD1 rodent models of retinal degeneration, the levels of apelin and its receptor were significantly up-regulated, which is consistent with them being under similar regulatory control. In many tissues, the expression patterns of Apln and Aplnr have been shown to be closely aligned, with Apln and Aplnr gene expression coordinated through SP1-mediated transcriptional regulation. 47, 48 Of note, it has been reported that a single-nucleotide polymorphism at an SP1 binding site in the 5= flanking region of the Aplnr gene induces Aplnr activity and confers an increased risk of cerebral infarct. 47 Although the mechanism is currently unknown, we might speculate that inceased microvascular tortuosity due to Apln/Aplnr-mediated remodeling may predispose to increased infarct susceptibility and hemorrhage in the brain.
Earlier reports have implicated Apln and Aplnr in retinal blood vessel development 31 with enhanced mRNA expression at the leading edge of the superficial plexus as it develops toward the periphery. 25, 28, 49 In the Apln Ϫ/Ϫ mouse, however, only minor transient delays in retinal vascular development have been reported. 31 We observed reduced branching of the deeper plexus at P14 and P21 in Apln Ϫ/Ϫ mice, as well as a significant decrease in the number of radial arteries and veins and an increase in the frequency of arteriovenous crossings, relative to C57BL/6J controls. Most notable, however, was the novel observation that Apln Ϫ/Ϫ mice have reduced remodeled radial veins. In control animals, an average of 2.1 radial veins in the superficial plexus remodel and become integrated into the deeper vascular plexus as it develops, becoming deep drainage venules. 15 The mechanism through which this occurs is currently unclear, but given that the deeper plexus arises from all radial veins, and not just the subset that remodels downward, it seems likely that this is a regulated process. Our data, therefore, support our hypothesis that apelin is an important regulator of this aspect of developmental vascular remodeling. Notably, other deep venules that result from branching from the radial veins were unaffected by loss of apelin, because they were present in both C57BL/6J and Apln Ϫ/Ϫ mice. Having established that apelin is required for some elements of developmental vascular remodeling in the retina, the question arose of whether, as suggested by the gene expression data, apelin is also required for pathogenic non-neovascular remodeling. The RD1 mouse is an ani-mal model of retinal degeneration that exhibits retinal vascular telangiectasia in the absence of any significant neoangiogenesis. We therefore generated Apln-knockout mice on the RD1 background to test whether the apelinergic pathway contributes to telangiectatic vascular remodeling. These mice exhibited a striking loss of telangiectatic vessels. Although the loss of some telangiectatic deep venules may result from the failure to develop remodeled veins, the number of telangiectatic capillaries not associated with these vessels was also reduced substantially. This provides compelling evidence that apelin is essential for pathogenic non-neovascular remodeling in the retina.
Apelin has been implicated in pathogenic neoangiogenesis. 26, 27, 29, [37] [38] [39] [40] [41] To gain further insight into the role of apelin in retinal vascular pathology, we investigated the role of apelin in the CNV and Vldlr Ϫ/Ϫ models of retinal neovascularization. Surprisingly, we observed no difference in the extent of CNV in Apln Ϫ/Ϫ mice, relative to wild-type controls; similarly, in the Apln/Vldlr doubleknockout mice the number of intraretinal neovascular growths was not significantly different from that observed in the Vldlr Ϫ/Ϫ mice. These data appear to be at odds with the recently reported effects of apelin in the mouse model of oxygen-induced ischemic retinopathy. The hypoxiainduced increase in retinal capillary density is attenuated at P15 and P17 in Apln-knockout mice. 39 However, retinal capillary density is already reduced in these mice at the age at which oxygen-induced ischemic retinopathy is induced 31 (our data not shown), making it unclear whether the effects are due primarily to loss of apelin or to the underlying delay in retinal vascular development in these animals. Furthermore, it is important to note that the effects are not permanent, because vessel density reaches parity between the wild type and Apln Ϫ/Ϫ by P84. 31 Alternatively, this discrepancy may reveal that, as is the case with TGF␤, the outcome of apelin signaling is extremely dependent on context. It may therefore be proposed that, in the presence of low VEGF expression (as in the RD1 mouse retina), the apelinergic pathway cannot independently promote sprouting angiogenesis and that its primary role is to drive non-neovascular modifications. In the presence of significantly elevated VEGF, however, apelin can either contribute to pathogenic vascular sprouting or have no effect, depending on the relative contribution of other differentially activated costimulatory pathways. This is supported by the finding that apelin exerts its effect on a corneal angiogenesis assay primarily through a cooperative process involving VEGF or FGF2. 31 It is entirely feasible, therefore, that in retinal pathological angiogenesis, in which hypoxia is the predominant driving factor, both apelin and VEGF combine to determine the extent of new blood vessel growth, 31, 45 whereas when additional contributing factors are involved, such as in CNV and in the Vldlr Ϫ/Ϫ mouse, the role of apelin in neovascularization is diminished. Our data, however, suggest that in the retina apelin is involved predominantly in developmental and pathogenic nonneovascular remodeling, because it has a marginal effect in physiological angiogenesis and no effect on pathological neovascularization observed in laser-induced CNV or Vldlr Ϫ/Ϫ mice. Over several decades, a great deal of information has been gathered describing the factors that regulate developmental, physiological, and pathological sprouting angiogenesis. Much less, however, is understood of the factors that control non-neovascular remodeling, despite its clear pathogenic importance. With the present study, we have demonstrated that apelin and its cognate receptor Aplnr are involved in remodeling of the vasculature in retinal development and disease and in the latter case may represent a novel target for therapeutic intervention.
